Meeting Banner
Abstract #2427

Ultra-high field Dynamic Contrast Enhanced Magnetic Resonance Imaging of the Breast with pharmacokinetic (PK) modeling: Value for the Differentiation of Benign and Malignant Breast Tumors and Molecular Breast Cancer Subtypes

Rosa Elena Ochoa Albiztegui1, Joao Vicente Machado Horvat1, Sunitha Thakur1, Blanca Bernard-Davila1, Siegfried Trattnig2, Thomas Helbich2, Elizabeth Morris1, and Katja Pinker-Domenig1

1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Biomedical Imaging and Image-guided Therapy, Medical University Vienna, Vienna, Austria

To investigate ultra-high field DCE-MRI of the breast at 7T with pharmacokinetic modeling for differentiation of benign and malignant breast tumors and molecular breast cancer subtypes. 37 patients with 43 breast lesion were included and underwent a 7T DCE-MRI of the breast. Quantitative pharmacokinetic imaging biomarkers ktrans and kep aid in the differentiation of benign and malignant breast tumors. Selection of ROI- using a whole tumor and a 10mm2 ROI- does not influence diagnostic accuracy. Quantitative pharmacokinetic imaging biomarkers ktrans and kep are not able to differentiate molecular breast cancer subtypes.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract